-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

Benzinga·09/10/2026 13:07:43
Listen to the news
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $100 price target.